Amgen says generic version of AbbVie's Humira worked as well as original in psoriasis study

IndustriesAssociated Press

Amgen said Wednesday that its generic version of Humira, the best-selling drug in the world, worked as well as the original medication in a late-stage clinical trial.

The study is one of two that Amgen is running to compare its generic, ABP 501, to Humira as a treatment for moderate to severe plaque psoriasis. Humira is also known as adalimumab, and it is used to treat a variety of conditions including Crohn's disease, rheumatoid arthritis, ulcerative colitis and plaque psoriasis.

Continue Reading Below

IMS Health says Humira, made by AbbVie Inc., is the biggest-selling brand-name drug in the world by dollar value. During the second quarter, revenue from Humira grew 26 percent to $3.29 billion.

Amgen Inc. shares rose $1.56 to $137.59.

The Thousand Oaks, California, company says it is studying a total of six generic versions of biotech drugs, or biosimilars. It wants to start marketing generic versions of those drugs in 2017. Biotech drugs are grown in living cells rather then produced with chemicals, so creating a generic duplicate is considered more difficult and carries more regulatory hurdles.

Shares of AbbVie rose 60 cents to $57.25.